Блог компании DayTraderClub | WALL STREET INTRADAY, WEDNESDAY

 Biggest point gainers: XEC 136.68(12.69), PXD 186.18(12.51), CXO 139.06(11.73), FANG 104.95(9.55), CLR 55.94(8.73), EOG 100.15(7.71),GS 218.88(7.13), PDCE 70.52(6.15), APC 66.02(5.86), SM 37.73(5.82), NFX 44.87(5.77), EGN 59.05(5.75), HES 54.79(5.74), SLCA 50.1(4.91),HAL 52.64(4.85), DVN 46.91(4.75), APA 65.16(4.42), HP 71.97(4.4), PE 37.33(4.37), LYB 88.09(4.37), TRGP 52.92(4.33), CRZO 39.42(4.25),WLK 58.6(4.19), RSPP 43.08(4.14), COP 48.29(4.06)

Biggest point losers: SHW 270.85(-5.47), CHTR 275.45(-5.04), COO 165.51(-4.64), NVRO 75.5(-4.56), ADSK 71.23(-4.03), DXCM64.23(-3.84), GWPH 112.6(-3.7), GWRE 54.14(-3.41), CI 135.06(-3.24), AVGO 172.44(-3.01), RARE 81.35(-2.84), ILMN 133.75(-2.79), AEO16.3(-2.62), BIIB 300.4(-2.38), RL 106.29(-2.32), RCL 80.73(-2.19), ALGN 93.36(-2.15), IBB 278.2(-2.11), TLT 120.12(-2.11), TQQQ126.21(-1.95), VLO 61.87(-1.9), JCOM 74.69(-1.85), AGN 190.79(-1.85), NEE 115.47(-1.8), NTNX 32.3(-1.79)

 Gainers on news:

• IsoRay (ISR +0.52%) announces highlights from its presentation at the 21st Annual Meeting of the Society for Neuro-Oncology
• Global Blood Therapeutics (GBT +3.22%) announces that the European Commission has designated GBT440 as an orphan medicinal product for the treatment of sickle cell disease
• Sangamo Biosci (SGMO +3.85%) announces that its collaborative zinc finger nuclease-mediated genome editing program for hemoglobinopathies will transfer to Bioverativ

Decliners on news:

• Arrowhead (ARWR -62.76%) will discontinue development of clinical stage drug candidates ARC-520, ARC-521, and ARC-AAT
• Cerecor (CERC -52.54%) announces top-line clinical results from its major depressive disorder Phase 2 clinical trial of adjunctive treatment of CERC-301; study misses primary endpoint
• Ocular Therapeutix (OCUL -3.97%) enters into controlled equity offering sales agreement to offer and sell shares of its common stock having an aggregate offering price of up to $40 mln

Gainers on earnings:

• Champions Oncology (CSBR +17.8%) reports Q3 EPS $0.00 vs ($0.20) year ago on revs +51.5% y/y to $4.5 mln and reaffirms annual revenue guidance; details new strategic emphasis
• RA Pharma (RARX +0.52%) reports Q3 results; on track to initiate Phase 2 Clinical Trial of RA101495 in 1Q 2017

Upgrades/Downgrades:

• Xtant Medical (XTNT +15.5%) initiated with a Buy at Aegis Capital; tgt $3.50
• Arbutus Biopharma (ABUS +12.26%) Chardan Capital Markets Upgraded to BUY (from Neutral) — Price Target: 4
• UnitedHealth (UNH +1.22%) target raised to $175 at RBC Capital Mkts
• Abaxis (ABAX -2.53%) downgraded to Neutral from Buy at Northcoast